(Q36858273)

English

A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer

scientific article published on 29 July 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

phase II clinical trial

0 references

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

author name string

J-L Lee

1

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Y-K Kang

2

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

H J Kang

3

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

K-H Lee

4

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

D Y Zang

5

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

B-Y Ryoo

6

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

J G Kim

7

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

S R Park

8

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

W K Kang

9

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

D B Shin

10

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

M-H Ryu

11

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

H M Chang

12

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

T-W Kim

13

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

J H Baek

14

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Y J Min

15

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

language of work or name

0 references

publication date

29 July 2008

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

99

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

4

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

584-590

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6604536

0 references

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527839

29 September 2017

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527839

29 September 2017

International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients--an analysis of the medical literature.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527839

29 September 2017

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527839

29 September 2017

A phase II Study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527839

29 September 2017

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527839

29 September 2017

Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527839

29 September 2017

Capecitabine as adjuvant treatment for stage III colon cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527839

29 September 2017

Global cancer statistics, 2002

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527839

29 September 2017

S-1 in gastric cancer: a comprehensive review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527839

29 September 2017

A case for geriatric oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527839

29 September 2017

First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527839

29 September 2017

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527839

29 September 2017

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527839

29 September 2017

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527839

29 September 2017

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527839

29 September 2017

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527839

29 September 2017

Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527839

27 June 2018

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527839

27 June 2018

Potential regional differences for the tolerability profiles of fluoropyrimidines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527839

4 September 2018

Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527839

4 September 2018

Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527839

4 September 2018

Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527839

4 September 2018

A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527839

4 September 2018

Participation of patients 65 years of age or older in cancer clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527839

4 September 2018

Re: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527839

4 September 2018

Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2527839

4 September 2018

Geriatric Oncology: A Field Coming of Age

1 reference

https://pubmed.ncbi.nlm.nih.gov/18665164

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations

1 reference

https://pubmed.ncbi.nlm.nih.gov/18665164

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/18665164

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the

1 reference

https://pubmed.ncbi.nlm.nih.gov/18665164

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Participation in cancer clinical trials: race-, sex-, and age-based disparities

1 reference

https://pubmed.ncbi.nlm.nih.gov/18665164

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18665164

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/18665164

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thalidomide use and digital gangrene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6604536

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6604536

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BJC.6604536

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36858273&oldid=2094888933"